Overview

Deal Terms

Company Profile

Deal Summary

Financials

Logos provided by Clearbit

Kurve Therapeutics

Platform

Rialto Markets

Start Date

08/02/2022

Close Date

Not Provided

Min. Goal

$580

Max. Goal

$50,000,000

Min. Investment

$580

Security Type

Equity - Common

Series

Series A

SEC Filing Type

RegA+    

Price Per Share

$5.80

Pre-Money Valuation

$291,787,299

Logos provided by Clearbit

Kurve Therapeutics

Year Founded

2019

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B

Margin

Medium

Capital Intensity

High

Location

Lynnwood, Washington

Business Type

Growth

Company Website

Kurve Therapeutics is raising funds through Reg A+ crowdfunding with Rialto Markets as the Broker-Dealer. The company has developed its patented Controlled Particle Dispersion (CPD) intranasal drug delivery technology. The technology creates a focused flow through the curved pathways of the nasal cavity and allows access to the olfactory region to treat neurogenerative diseases. Kurve Therapeutics’ technology has been featured in multiple publications and has completed Phase II studies on Alzheimer’s patients. Marc Giroux, Tom McDowell, and Glenn Cornett founded Kurve Therapeutics in 2019. The current crowdfunding campaign has a maximum target of $50,000,000. The campaign proceeds will be used for asset purchase, marketing, clinical studies, contract manufacturing, and working capital.

Balance Sheet

Cash and Cash Equivalents	$373,804
Accounts and Notes Receivable	$15,000
Total Assets	$640,574

Accounts Payable & Accrued Liabilities	$28,331
Long Term Debt	$507,500
Total Liabilities	$606,726
Total Stockholders' Equity	$33,848
Total Liabilities and Equity	$640,574

Statement of Comprehensive Income Information

Total Revenues	$70,700
Costs & Expenses Applicable to Rev	$128,344
Net Income	$-65,427

Earnings Per Share - Basic	$0.00
Earnings Per Share - Diluted	$0.00

Auditor: Assurance Dimensions

Financials as of: 08/02/2022

Create a free account today to gain access to KingsCrowd analytics.

No company has been able to develop an FDA-approved treatment that stops Alzheimer’s in its tracks. Kurve Therapeutics has the potential to change that with its potentially groundbreaking device. But its long road to FDA approval and its inexperienced team may threaten the company’s survival.

Buy the Full Report

Kurve Therapeutics Founder Marc Giroux on Treating Alzheimer’s and More

The central nervous system (CNS) disorder umbrella houses a number of familiar names, like Alzheimer’s, Parkinson’s, and multiple sclerosis. These conditions are often life-altering to sufferers, and many are incurable. Thankfully, treatments are available, and scientists aren’t done looking for new solutions.

Kurve Therapeutics is fighting CNS disorders right up the nose with its patented Controlled Particle Dispersion technology. This intranasal technology delivers drugs noninvasively and painlessly, and it makes treatments more precise and effective. We reached out to founder and CEO Marc Giroux to hear about why he originally started working on the technology and how Kurve Therapeutics overcame assumptions.

Note: This interview was conducted over phone and email. It has been lightly edited for clarity and length.

Read Founder Interview